Protara Therapeutics (TARA) AI Stock Analysis

• Market Cap: $267.18M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: 48.84%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 54,084,377
• 10 Day Avg. Volume: 993,301
• 30 Day Avg. Volume: 1,264,100
• PEG Ratio: 0.10
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.04
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -797.42
• Enterprise Value/Ebitda: -2.36
• 1Y Price Target: $26.00
• Price Target Upside: 426.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.49
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $5.00 ▲(1.21% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is held down mainly by weak financial performance (no revenue, recurring losses, and ongoing cash burn) and soft technicals (price below key moving averages with negative MACD). Offsetting these are constructive corporate developments (positive Phase 2 update and clearer registrational path) and a stronger, low-debt balance sheet, while valuation support is limited due to negative earnings and no dividend.

Positive Factors

Clinical efficacy — TARA-002 Phase 2

Robust, durable complete response rates and favorable tolerability in Phase 2 strengthen the program's probability of achieving registrational endpoints. Durable clinical efficacy reduces execution risk for development and supports long-term commercial potential in NMIBC if confirmed.

Negative Factors

No revenue; persistent operating losses

As a pre-commercial biotech with no product revenue, ongoing operating losses are structural until commercialization or meaningful partnerships occur. Persistent losses depress returns and mean reliance on external capital will likely continue over the medium term.

Protara Therapeutics Business Overview & Revenue Model

Company Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cel...

Read more

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cel...

How the Company Makes Money

Protara Therapeutics is a clinical-stage company and generally does not generate recurring revenue from product sales because its programs are under development rather than broadly commercialized. Its funding and cash inflows have primarily come f...

Read more

Protara Therapeutics is a clinical-stage company and generally does not generate recurring revenue from product sales because its programs are under development rather than broadly commercialized. Its funding and cash inflows have primarily come f...

Protara Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-362.00K	0.00	-341.00K	0.00	0.00
EBITDA	-64.19M	-48.82M	-43.27M	-64.57M	-45.40M
Net Income	-57.44M	-44.60M	-40.42M	-65.95M	-47.25M
Balance Sheet
Total Assets	209.47M	181.45M	78.95M	113.29M	172.60M
Cash, Cash Equivalents and Short-Term Investments	155.55M	170.29M	65.58M	84.37M	91.23M
Total Debt	3.36M	4.48M	5.47M	6.38M	7.24M
Total Liabilities	13.06M	14.32M	10.63M	11.21M	10.68M
Stockholders Equity	196.41M	167.13M	68.32M	102.08M	161.91M
Cash Flow
Free Cash Flow	-56.46M	-35.87M	-37.60M	-26.58M	-35.10M
Operating Cash Flow	-56.37M	-35.81M	-37.56M	-26.46M	-34.50M
Investing Cash Flow	-139.49M	19.16M	53.11M	14.95M	-98.19M
Financing Cash Flow	82.72M	139.87M	-91.00K	-90.00K	-228.00K

Protara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARA, the sentiment is Negative. The current price of 4.94 is below the 20-day moving average (MA) of 5.50, below the 50-day MA of 6.06, and above the 200-day MA of 4.77, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 37.30 is Neutral, neither overbought nor oversold. The STOCH value of 39.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TARA.

Protara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OBIO	52 Neutral	$249.30M	-3,008.78	-169.64%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZURA	51 Neutral	$562.64M	-4.97	-83.86%	―	―	-19.69%
PLX	50 Neutral	$172.42M	-21.41	-13.46%	―	35.42%	―
TARA	49 Neutral	$267.18M	-3.97	-36.38%	―	―	48.84%
SKYE	45 Neutral	$19.26M	-0.53	-143.59%	―	―	-53.18%
HURA	41 Neutral	$109.90M	-4.42	-193.06%	―	―	99.21%

Protara Therapeutics Corporate Events